Clinical Trial Search

Phase 3 N=129 A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Primary: Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI) — 81; 2.2 percentage of participants…

Xian-Janssen Pharmaceutical Ltd. Results Mar 2014 3.9% serious AE View details

Phase 3 N=130 Long-term Safety Study for GSK573719/GW642444 in Japanese

Pulmonary Disease, Chronic Obstructive

Primary: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period — 113; 16 Participants

GlaxoSmithKline Results Mar 2014 12.3% serious AE View details

Phase 3 N=36 Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A or B With Inhibitors · Hemophilia A · Hemophilia B

Primary: Reduction in Annualized Bleeding Episode Rate (ABR) Among Participants Receiving Prophylactic Treatment as Compared to Those Treated On-demand — 28.7; 7.9 bleeds/year…

Baxalta now part of Shire Results Mar 2014 36.1% serious AE View details

Phase 3 N=267 Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Primary Myelofibrosis · MPN-associated Myelofibrosis

Primary: Percentage of Participants Who Achieved RBC-Transfusion Independence — 17.3; 16.7 percentage of participants — p=1.000

Celgene Results Mar 2014 39.6% serious AE View details

Phase 3 N=250 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

Kidney Cancer · Leukemia · Lymphoma

Primary: Neurotoxicity as Measured by a Scored Neurologic Examination at Baseline, 5 Weeks, and 10 Weeks (if Applicable) — 26; 34 percentage of participants

University of South Florida Results Mar 2014 6.0% serious AE View details

Phase 3 N=328 Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

Open-Angle Glaucoma · Ocular Hypertension

Primary: Mean Diurnal IOP Change From Baseline at Week 8 — -6.84; -6.00 millimeters mercury (mmHg)

Alcon Research Results Mar 2014 0.3% serious AE View details

Phase 3 N=615 A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Arthritis, Psoriatic

Primary: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24. — 22.8; 42.4; 49.5; 46.0 Percentage of participants — p=<0.001

Janssen Research & Development, LLC Results Mar 2014 4.5% serious AE View details

Phase 3 N=41 A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder

Primary: Young Mania Rating Scale (YMRS) — -18.8 scores on a scale

Otsuka Pharmaceutical Co., Ltd. Results Mar 2014 9.8% serious AE View details

Phase 3 N=125 Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above

Human Influenza

Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf — 17; 36; 95; 80…

Novartis Vaccines Results Mar 2014 0.0% serious AE View details

Phase 3 N=50 Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Exocrine Pancreatic Insufficiency · Chronic Pancreatitis · Pancreatectomy

Primary: Percent Coefficient of Fat Absorption (CFA) — 85.52; 58.02 percent CFA — p=<0.0001

Forest Laboratories Results Mar 2014 4.0% serious AE View details

Phase 3 N=82 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Chronic Pancreatitis · Exocrine Pancreatic Insufficiency

Primary: Percent Coefficient of Fat Absorption (CFA) of Participants Treated With High Dose EUR-1008 and Low Dose EUR-1008 — 88.87; 89.86 percent CFA — p=0.228

Forest Laboratories Results Mar 2014 2.6% serious AE View details

Phase 3 N=1,887 Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Contraception · Ovulation Inhibition · Contraceptives, Oral

Primary: Pearl Index — 1.65; 1.92 Pregnancies per 100 years of exposure

Bayer Results Mar 2014 1.1% serious AE View details

Phase 3 N=31 Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

Cystic Fibrosis · Exocrine Pancreatic Insufficiency

Primary: Percent Coefficient of Fat Absorption (CFA) — 88.55; 55.61 Percent CFA — p=<0.0001

Forest Laboratories Results Mar 2014 1.6% serious AE View details

Phase 3 N=676 LEO 90105 Ointment in Japanese Subjects With Psoriasis

Psoriasis

Primary: Change From Baseline in Modified Psoriasis Area and Severity Index (mPASI) — -50.5; -64.3; -53.6 percentage of change

LEO Pharma Results Mar 2014 0.6% serious AE View details

Phase 3 N=27 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder

Generalized Social Phobia

Primary: Clinical Global Impression (Change Version, Also Known as Improvement Version) — 3; 4 participants

University of California, San Diego Results Mar 2014 0.0% serious AE View details